MLL
Munich Leukemia Laboratory Leukemia diagnostics for safe lab results with diagnostics laboratory MLL

Diagnostics

We are the interdisciplinary experts

Our optimized diagnoses based on an extensive spectrum of methods help to extend life expectancy with improved quality of life.

To diagnostic offer

Methods

The foundation for a specific therapy

Expertise, focus topics, state-of-the-art technology and tireless research – combined with our unwavering commitment to progress – guarantee optimized and individual diagnosis.

To the methods

New: Englisch lab request form


Please see our new English lab request form including a detailed overview of the spectrum of our hematological diagnostics.

Open request form

Facts

  • 840529
    840529

    Samples received since 2005

  • 604
    604

    Publications

  • 202
    202

    Employees

MLL Magazine

Stay up to date

Here you will find all MLL News as well as scientific contributions to leukemia diagnostics and research.

to the MLL Magazine

Current Articles

  • Dr. rer. nat. Frank Dicker
    from 14.06.2021
    Diagnostics
    4-stage (4-tier) system for evaluating sequence variants

    Sequence alterations have classically been divided into two categories: "mutation" and "polymorphism". However, the rapid increase in sequencing data from healthy and various diseased tissues has made it obvious that there is a broad spectrum between clearly disease-associated pathogenic alterations and non-pathogenic polymorphisms. As of now, we are working in molecular genetics with the world's most widely used 4-tier classification system, which we have adapted to central questions in hematological diagnostics. We would like to introduce this to you in this article.

    Post review
    Read article
  • Prof. Dr. med. Dr. phil. Torsten Haferlach
    from 11.06.2021
    Diagnostics
    The logic of next generation sequencing wherever myeloid neoplasia is suspected

    Recently, S. Vantyghem et al (Haematologica 3/1/2021, pages 701–707)1,2 published a “real-life study.” The analyses were focused on 177 patients with suspected or already confirmed myeloid neoplasias such as MDS or MPN without a final diagnosis using cytomorphology and immunophenotyping. In a first cohort, an NGS panel with 34 genes was used either to exclude or confirm a definitive diagnosis. In a second cohort, the extent to which prognostic and especially therapeutic consequences would have to be drawn if somatic mutations were detectable was investigated. I would like to introduce this study to you in this article.

    Post review
    Read article

Events

Newsletter registration

Sign up for our MLL News and receive information on latest findings in leukemia diagnostics and research. Newsletter only available in German.